[Federal Register Volume 80, Number 141 (Thursday, July 23, 2015)] [Notices] [Page 43782] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2015-18024] [[Page 43782]] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2007-D-0369] Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 30, 2015 (80 FR 37273). The document announced the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The document was published with an incorrect table title and contents. This document corrects those errors. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115. SUPPLEMENTARY INFORMATION: In FR Doc. 2015-16013, appearing in the Federal Register of Tuesday, June 30, 2015, the following corrections are made: 1. On page 37274, in the first column, the title of table 2, ``Table 2. Revised Draft Product-Specific BE Recommendations for Drug Products Cholestyramine'' is corrected to read ``Table 2. Revised Draft Product-Specific BE Recommendations for Drug Products''. 2. On page 37274, in the first column, in the first line of the table under table 2, ``Cholestyramine'' is added to precede ``Doxycycline hyclate, Prasugrel hydrochloride, Tiagabine hydrochloride''. Dated: July 17, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015-18024 Filed 7-22-15; 8:45 am] BILLING CODE 4164-01-P